Copyright: ©Author(s) 2026.
World J Clin Cases. Jun 6, 2026; 14(16): 120945
Published online Jun 6, 2026. doi: 10.12998/wjcc.v14.i16.120945
Published online Jun 6, 2026. doi: 10.12998/wjcc.v14.i16.120945
Table 2 Details regarding seizure, antiseizure medication, and baseline vitamin D level
| Characteristics | Values [mean ± SD or median (IQR)] | Values, n (%) |
| Age at onset of seizure (year) | 6.5 ± 3.9 | - |
| Duration of seizure prior to start of ASM (month) | 1 (0-6) | - |
| Duration of ASM (month) | 4.3 ± 1.1 | - |
| Baseline vitamin D [25(OH)D] level (ng/mL) in different treatment groups | ||
| Monotherapy | 21.84 ± 10.1 | 61 (40.7) |
| Polytherapy | 20.12 ± 9.3 | 89 (59.3) |
| Enzyme-inducing ASM1 | 19.97 ± 9.6 | 62 (41.3) |
| Non-enzyme-inducing ASM2 | 21.15 ± 9.8 | 88 (58.7) |
- Citation: Sahoo PS, Jena DP, Mishra P, Sahu PK, Das RR. Serum vitamin D level and its association with anti-seizure medications in children with seizure disorder. World J Clin Cases 2026; 14(16): 120945
- URL: https://www.wjgnet.com/2307-8960/full/v14/i16/120945.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v14.i16.120945